Arch Biopartners Inc. Advances Kidney Injury Trial with Toronto General Hospital Collaboration
- Arch Biopartners Inc. partners with Toronto General Hospital for a Phase II trial of the LSALT peptide for kidney injury.
- The trial aims to enroll 240 participants to evaluate cardiac surgery-associated acute kidney injury within seven days post-surgery.
- CEO Richard Muruve emphasizes expanding patient recruitment to enhance the study's relevance and improve kidney health outcomes.
Toronto General Hospital Joins Arch Biopartners’ Groundbreaking Kidney Injury Trial
Arch Biopartners Inc. announces an important milestone in its clinical development efforts, as Toronto General Hospital obtains ethics board approval from the University Health Network (UHN) to participate in the Phase II clinical trial for the LSALT peptide. This approval allows the hospital to initiate patient recruitment, making it the seventh site activated globally and the second in Canada for this critical study. The Phase II trial aims to enroll 240 participants and employs a randomized, double-blind, placebo-controlled design to evaluate the incidence of cardiac surgery-associated acute kidney injury (CS-AKI) within seven days post on-pump cardiac surgery, utilizing the KDIGO criteria for diagnosis.
CS-AKI is a significant concern in cardiac surgery, affecting up to 30% of patients and contributing to elevated risks of morbidity and mortality. The LSALT peptide, Arch Biopartners’ leading drug candidate, is specifically engineered to address inflammation-induced kidney damage by targeting the dipeptidase-1 (DPEP1) pathway. Preliminary pre-clinical studies have shown promising results for the LSALT peptide in preventing ischemia-reperfusion injury (IRI), a frequent complication in kidney surgeries. The ongoing trial seeks to further validate these findings in a clinical setting, with the potential to significantly improve outcomes for patients undergoing cardiac procedures.
CEO Richard Muruve expresses optimism regarding the recent approval and its implications for the trial. He indicates that patient recruitment strategies will be adjusted to encompass a broader demographic, enhancing the study's relevance and applicability. The inclusion of Toronto General Hospital marks a vital step in Arch Biopartners’ mission to provide innovative solutions to acute kidney injury, a condition that remains largely unaddressed in the current medical landscape. In addition to the LSALT peptide, Arch is also advancing other drug candidates, including cilastatin, which aims to reduce toxin uptake into the kidneys, further demonstrating the company's commitment to combatting urgent health issues.
Arch Biopartners Inc. continues to position itself at the forefront of kidney health innovation, with its promising trial in collaboration with Toronto General Hospital and UHN. As the company progresses with its clinical endeavors, it remains focused on advancing therapies that can address the widespread and challenging issue of acute kidney injury, ultimately striving to enhance patient care and outcomes in the field of cardiac surgery.
